PharmiWeb Recruiter Blog

• Sanofi gains exclusive license to Innate’s B7H3 ANKET^TM program and options for two additional targets; Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization

Paris, December 19, 2022 Sanofi (NASDAQ: SNY) and Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced today an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET^TM (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKET^TM targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization. Innate and Sanofi signed a first NK cell engagers collaboration in 2016 for the generation and evaluation of up to two bispecific NK cell engagers, which are currently being evaluated by Sanofi’s R&D team, with one of these molecules already in clinical studies.

Valeria Fantin, Ph.D.
Global Head of Oncology Research at Sanofi
“At Sanofi, we are exploring the potential of NK cells for cancer immunotherapy, a key pillar for our oncology strategy. Our relationship with Innate aligns with our commitment to work with promising French companies and supports our ambition to develop a diverse portfolio of next-generation NK cell engagers, highly synergistic with Sanofi’s allogeneic NK cell platform, engineered lymphokines that stimulate NK cells, and growing Immuno-oncology pipeline. As a leading global company with roots in France, we are proud to collaborate to support the French healthcare ecosystem."

New collaboration leverages MyEyeDr.’s 850+ offices across the US to refer patients into ophthalmology and other therapeutic area clinical trials, expands Parexel’s Community Alliance Network to bring trials to patients where they are

BOSTON and DURHAM, N.C., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced a formal agreement with MyEyeDr., a leading vision healthcare organization, to refer its patients into existing and future ophthalmology clinical trials. Parexel and MyEyeDr. are currently collaborating on recruitment for a diabetic retinopathy clinical trial with future plans to expand into additional therapeutic areas such as endocrinology.

For the first time, Lilly will supply API at a significantly reduced price along with pro-bono technical assistance, enabling EVA Pharma to manufacture and supply insulin to at least one million people in lower income countries

Dublin, Ireland – 13 December 2022 – ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been recognised with a number of coveted business and industry awards over the second half of 2022 for delivering clinical research services, alongside specialist collaborations on data, analytics and digital healthcare.

• Location offers closer proximity to UK capital’s fast-growing global Life Sciences hub, Knowledge Quarter and world-class academic institutions
• Building and location will help GSK achieve ambitious sustainability targets
• Company to open new headquarters in 2024

GSK plc (LSE/NYSE: GSK) today announced that its new global headquarters will be in central London. The company will move to the new headquarters in 2024 from its current location in Brentford, West London.

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Imago BioSciences, Inc. (Nasdaq: IMGO). On Nov. 21, 2022, Merck announced that it had entered into a definitive agreement to acquire Imago.

Today, Novozymes and Chr. Hansen have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies. The combination is expected to unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large.

New Space Will Be Three Times Larger and Increase Testing Capabilities

The CNS specialist continues its strong expansion course in Europe and increases its presence from two to 20 countries in just six years

• Collaboration leverages HotSpot's Smart Allostery™ drug discovery platform for the development of the first and only small molecule IRF5 (interferon regulatory factor 5) inhibitor for the potential treatment of autoimmune diseases
• HotSpot to receive an upfront cash payment of $40 million with potential for further milestones and royalties

NORTH CHICAGO, Ill. and BOSTON, Dec. 6, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) and HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced an exclusive worldwide collaboration and option to license agreement for HotSpot's discovery-stage IRF5 program for the treatment of autoimmune diseases.